Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Salipro Biotech Expands Global Intellectual Property Portfolio with Granted Patents in Australia and Singapore
2024-12-05
Salipro Biotech strengthens its global intellectual property portfolio with granted patents in Singapore and Australia, protecting its proprietary Salipro® platform technology to enable the development of therapeutics against challenging drug targets.
Stockholm, Sweden, December 5, 2024 – Salipro Biotech AB, a Swedish biotechnology company focused on advancing drug discovery for challenging drug targets, today announced the issuance of granted patents in both Singapore and Australia for its Salipro® platform technology, a novel and proprietary method for directly isolating and purifying native membrane proteins, which are important targets for many therapeutic drugs. The Salipro® platform enables entirely novel drug discovery programs, including antibody discovery, small molecule drug screening and structure-based drug design.
The patents, entitled “Production of Salipro® Particles” (Australian Patent No. 2020257991; Singaporean Patent No. 11202111111U), cover processes implemented in the Salipro® platform and represent an important milestone that strengthens Salipro Biotech’s position as a key drug discovery platform holder for difficult drug targets such as GPCRs, ion channels and transporters.
Access the full press release.
Salipro to join the upcoming PEGS Europe conference
2024-10-29
Salipro Biotech is heading to PEGS Europe 2024, taking place in Barcelona (Spain), November 5-7!
Our Business Development Director, Peter Jahnmatz, will be there to present new exciting data from our latest collaborations on GPCR-targeted drug discovery.
If you are also attending, take the chance to meet Peter by his poster (B93) to exchange ideas on how the Salipro® platform can advance your drug discovery programs against complex membrane protein targets.
Let’s meet at PEGS and discuss exciting collaborations!
Salipro at BIO-Europe 2024 in Stockholm, Sweden
2024-10-24
We are excited to announce that Salipro Biotech will be part of the Swedish Pavilion at the 30th BIO-Europe conference taking place here in Stockholm, Sweden, from November 4-6, 2024!
The Swedish pavilion, located in booth 94, will showcase Salipro and serve as a hub for connecting with us and with other Swedish companies in the life science sector.
Our CEO, Jens Frauenfeld, and our BD Manager, Lorena Galán, will be onsite, meeting with current pharma and biotech partners as well as connecting with new parties to discuss drug discovery involving membrane protein drug targets such as CXCR4, GPR75, PANX1 and more.
Attending BIO-Europe 2024? Feel free to connect with our delegates and schedule a meeting via the PartneringONE platform:
https://partneringone.informaconnect.com/event/774/profile/user/2078/company/1175
We look forward to face-to-face business meetings with industry leaders and the opportunity to explore new partnerships!